Cellectis S.A. (CLLS) Reaches New 52-Week High at $32.18
Cellectis S.A. (NASDAQ:CLLS) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $32.18 and last traded at $32.18, with a volume of 608,287 shares traded. The stock had previously closed at $28.76.
CLLS has been the subject of several research reports. Jefferies Group LLC set a $47.00 price target on shares of Cellectis and gave the stock a “buy” rating in a research note on Friday, August 25th. Zacks Investment Research upgraded shares of Cellectis from a “hold” rating to a “buy” rating and set a $32.00 price objective for the company in a research note on Wednesday, July 19th. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of Cellectis in a research note on Saturday, June 3rd. Finally, BidaskClub lowered shares of Cellectis from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. Cellectis has a consensus rating of “Buy” and a consensus price target of $41.80.
The stock’s market capitalization is $1.15 billion. The firm’s 50 day moving average price is $25.11 and its 200-day moving average price is $24.03.
Several hedge funds have recently added to or reduced their stakes in CLLS. ARK Investment Management LLC lifted its position in shares of Cellectis by 79.1% during the second quarter. ARK Investment Management LLC now owns 4,038 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 1,784 shares during the last quarter. Eqis Capital Management Inc. purchased a new stake in shares of Cellectis during the first quarter valued at about $202,000. Trexquant Investment LP purchased a new stake in shares of Cellectis during the first quarter valued at about $214,000. Williams Jones & Associates LLC purchased a new stake in shares of Cellectis during the second quarter valued at about $244,000. Finally, Wells Fargo & Company MN lifted its position in shares of Cellectis by 132.1% during the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock valued at $247,000 after buying an additional 5,435 shares during the last quarter. 14.85% of the stock is owned by institutional investors and hedge funds.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.